1. Atopy modifies the association between inhaled corticosteroid use and lung function decline in patients with asthma
- Author
-
Isabelle Pin, Isa Cerveri, Lucia Cazzoletti, Andrei Malinovschi, Josep M. Antó, Simone Accordini, Deborah Jarvis, David Gislason, Ane Johannessen, Bénédicte Leynaert, Pierpaolo Marchetti, Diogenes S. Ferreira, Nicole Probst-Hensch, Alessandro Marcon, Christer Janson, Rain Jögi, Judith Garcia-Aymerich, Angelo Corsico, Joachim Heinrich, Joost Weyler, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 2610, 4350 97/0035-01, 99/0034-01, 99/0034-02 97/0035, 97/0035-02, 99/0034-04, 99/0034-06, 99/0034-07, 99/350 90MR/10, 91AF/6 SEPAR R01 HL62633-01 018996 911631 Russell Sage Foundation, RSF ResMed Foundation AstraZeneca GlaxoSmithKline, GSK Novartis U.S. Public Health Service, USPHS: R01 HL62633-01 Chiesi Farmaceutici, Chiesi Faculty of Arts and Sciences, Harvard University, FAS Boehringer Ingelheim VÃ¥rdalstiftelsen Freiwillige Akademische Gesellschaft, FAG Commercial Aircraft of China, COMAC Wellcome Trust, WT: WT 084703MA Horizon 2020 Framework Programme, H2020: 633212 Growing Spine Foundation, GSF Gobierno del Principado de Asturias Blond McIndoe Research Foundation, BMRF Asthma and Allergy Foundation of America, AAFA Ministerio de Sanidad, Consumo y Bienestar Social, MISAN Union Chimique Belge, UCB Medical Research Council, MRC: 92091, G0901214 National Institute for Health Research, NIHR British Lung Foundation, BLF European Commission, EC: EU-PEAL PL01237 National Health and Medical Research Council, NHMRC: G.0402.00 Asthma Foundation of Victoria Deutsche Forschungsgemeinschaft, DFG: FR1526/1-1, HE 3294/10-1, MA 711/4-1, MA 711/6-1, NO 262/7-1 Agence Nationale de la Recherche, ANR Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNSF: 3100-059302, 3200-042532, 3200-052720, 3247-065896, 3247BO-104283, 3247BO-104284, 3247BO-104288, 33CSCO-108796, 33CSCO-134276/1, 4026-028099, 4026-28099 Eesti Teadusfondi, ETF: 1088 ForskningsrÃ¥det för Arbetsliv och Socialvetenskap, FAS Eesti Teadusagentuur: 562 Bundesamt für Gesundheit, BAG Belgian Federal Science Policy Office, BELSPO Generalitat de Catalunya Consell Català de Recerca i Innovació: 1999SGR 00241 Haridus- ja Teadusministeerium: SF0180060s09 Hjärt-Lungfonden Consiglio Nazionale delle Ricerche, CNR Instituto de Salud Carlos III, ISCIII: C03/011, C03/09 Háskóli Ãslands, HI Norges ForskningsrÃ¥d: 101422/310, 214123 Medicinska ForskningsrÃ¥det, MFR Cancéropôle Ile de France Russian Science Foundation, RSF: 381/05.93 Ministeriet Sundhed Forebyggelse SUVA Sociedad Española de Neumología y Cirugía Torácica, SEPAR: FIS 09/01511, FIS PS09/00716, FIS PS09/02185, FIS PS09/03190, SEPAR 1001/2010 Horizon 2020 Universiteit Antwerpen Comité des Maladies Respiratoires de l'Isère Comissió Interdepartamental de Recerca i Innovació Tecnològica, CIRIT: 1997 SGR 00079, 1999 SGR 00214 Servicio Murciano de Salud Regione del Veneto Regione Piemonte Astma- och Allergiförbundet Centre Hospitalier Universitaire de Bordeaux, CHU de Bordeaux Office Fédéral de l'Education et de la Science, OFES Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie, BMBWF Helmholtz Zentrum München Lungenliga Schweiz Ministerio de Medio Ambiente y Medio Rural y Marino, MARM: G03/176 Ministère des Solidarités et de la Santé INCLIVA Instituto de Investigación Sanitaria: 91/0016-060-05/E, 92/0319, 93/0393, PS09/00716, PS09/01511, PS09/02185, PS09/02457, PS09/03190 Fundació Autònoma Solidària, FAS Servicio Andaluz de Salud, SAS, The ALEC study is funded by the European Union's Horizon 2020 Research and Innovation programme under grant agreement number 633212. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. National funders who supported data collection in the original studies are listed in Appendix E4 in this article's Online Repository at www.jaci-inpractice.org. The funders had no role in the writing of the manuscript or the decision to submit it for publication.Conflicts of interest: D. S. Ferreira reports grants from the Asthma Foundation of Victoria, Allen and Hanburys, National Health and Medical Research Council. I. Pin reports travel grants and honoraria from Novartis, Zambon, and AstraZeneca, and nonfinancial support from AGIR?dom. R. J?gi reports grants from Estonian Research Council Personal Research (grant no. 562), and consultancy, lecture, and travel fees from GlaxoSmithKline, Boehringer, and Novartis. The rest of the authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.Financial support for ECRHS I: The coordination of this work was supported by the European Commission, and the authors and participants are grateful to the late C. Baya and M. Hallen for their help during the study and K. Vuylsteek and the members of the COMAC for their support. The following grants helped to fund the local studies: Australia: Asthma Foundation of Victoria, Allen and Hanbury's, Belgium: Belgian Science Policy Office, National Fund for Scientific Research, Estonia: Estonian Science Foundation (grant no. 1088), France: Minist?re de la Sant?, Glaxo France, Institut Pneumologique d'Aquitaine, Contrat de Plan Etat-R?gion Languedoc-Rousillon, Caisse nationale de l'assurance maladie des travailleurs salari?s, Comit? national contre les maladies respiratoires et la tuberculose (90MR/10, 91AF/6), Ministre delegu? de la sant?, R?seau national de sant? publique, France, Germany: Helmholtz Zentrum Munich and Bundesminister f?r Forschung und Technologie, Italy: Ministero dell'Universit? e della Ricerca Scientifica e Tecnologica, Consiglio Nazionale delle Ricerche, Regione Veneto (grant RSF no. 381/05.93), Norway: Norwegian Research Council project no. 101422/310, Portugal: Glaxo Farmac?utica Lda, Sandoz Portugesa, Spain: Fondo de Investigaci?n Sanitaria (nos. 91/0016-060-05/E, 92/0319, and 93/0393), Hospital General de Albacete, Hospital General Juan Ram?n Jim?nez, Direcci?n Regional de Salud P?blica (Consejer?a de Sanidad del Principado de Asturias), Consell Interdepartamental de Recerca i Innovaci? Tecnol?gica (1997 SGR 00079), and Servicio Andaluz de Salud, Sweden: The Swedish Medical Research Council, the Swedish Heart-Lung Foundation, the Swedish Association against Asthma and Allergy, Switzerland: Swiss National Science Foundation (grant no. 4026-28099), and UK: National Asthma Campaign, British Lung Foundation, Department of Health, South Thames Regional Health Authority.Financial support for ECRHS II: Australia: National Health and Medical Research Council, Belgium: Antwerp: Fund for Scientific Research (grant code G.0402.00), University of Antwerp, and Flemish Health Ministry, Estonia: Tartu: Estonian Science Foundation (grant no. 4350), France: (All) Programme Hospitalier de Recherche Clinique?Direction de la Recherche Clinique de Grenoble 2000 number 2610, Ministry of Health, Minist?re de l'Emploi et de la Solidarit?, Direction G?nerale de la Sant?, Centre Hospitalier Universitaire de Grenoble, Bordeaux: Institut Pneumologique d'Aquitaine, Grenoble: Comite des Maladies Respiratoires de l'Isere, Montpellier: Aventis (France), Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon, Paris: Union Chimique Belge-Pharma (France), Aventis (France), Glaxo France, Germany: Erfurt: GSF?National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code FR1526/1-1), Hamburg: GSF?National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code MA 711/4-1), Iceland: Reykjavik: Icelandic Research Council and Icelandic University Hospital Fund, Italy: Pavia: GlaxoSmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), and Local University Funding for Research 1998 and 1999, Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico?Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Verona: Ministero dell'Universit? e della Ricerca Scientifica (MURST), Glaxo Wellcome s.p.a., Norway: Bergen: Norwegian Research Council, Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, and Norway Research Fund, Spain: Fondo de Investigacion Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Hospital Universitario de Albacete, Consejeria de Sanidad, Barcelona: Sociedad Espanola de Neumolog?a y Cirug?a Toracica, Public Health Service (grant code R01 HL62633-01), Fondo de Investigaciones Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Consell Interdepartamentalde Recerca i Innovaci? Tecnol?gica (grant code 1999SGR 00241), Instituto de Salud Carlos III, Red de Centros de Epidemiolog?a y Salud P?blica, C03/09, Red de Bases moleculares y fisiol?gicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176, Huelva: Fondo de Investigaciones Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Galdakao: Basque Health Department, Oviedo: Fondo de Investigaciones Sanitaria (97/0035-02, 97/0035, 99/0034-01, 99/0034-02, 99/0034-04, 99/0034-06, 99/350, and 99/0034-07), European Commission (EU-PEAL PL01237), Generalitat de Catalunya (CIRIT 1999 SGR 00214), Hospital Universitario de Albacete, Sociedad Espa?ola de Neumolog?a y Cirug?a Tor?cica (SEPAR R01 HL62633-01), Red de Centros de Epidemiolog?a y Salud P?blica (C03/09), Red de Bases moleculares y fisiol?gicas de las Enfermedades Respiratorias (C03/011), and Red de Grupos Infancia y Medio Ambiente (G03/176, 97/0035-01, 99/0034-01, and 99/0034-02), Sweden: G?teborg, Umea, AND Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation, and Swedish Council for Working Life and Social Research (FAS), Switzerland: Basel: Swiss National Science Foundation, Swiss Federal Office for Education and Science, and Swiss National Accident Insurance Fund, UK: Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign).Financial support for ECRHS III: Australia: National Health and Medical Research Council, Belgium: Antwerp: South and Antwerp City: Research Foundation Flanders (grant code G.0.410.08.N.10), Estonia: Tartu: the Estonian Ministry of Education (SF0180060s09), France: (All): Minist?re de la Sant?, Programme Hospitalier de Recherche Clinique national 2010, Bordeaux: INSERM U897 Universit? Bordeaux segalen, Grenoble: Comite Scientifique AGIRadom 2011, and Paris: Agence Nationale de la Sant?, R?gion Ile de France, domaine d'int?r?t majeur, Germany: Erfurt: German Research Foundation (HE 3294/10-1), Hamburg: German Research Foundation (MA 711/6-1, NO 262/7-1), Iceland: Reykjavik: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation, California, USA, Orkuveita Reykjavikur (Geothermal plant), and Vegager?in (The Icelandic Road Administration, Italy: All Italian centers were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition, Verona was funded by Cariverona Foundation and Education Ministry (Ministero dell'Istruzione, dell'Universit? e della Ricerca), Norway: Norwegian Research Council (grant no. 214123), Western Norway Regional Health Authorities (grant no. 911631), and Blond McIndoe Research Foundation, Spain: Fondo de Investigaci?n Sanitaria (PS09/02457, PS09/00716, PS09/01511, PS09/02185, PS09/03190), Servicio Andaluz de Salud, Sociedad Espa?ola de Neumolog?a y Cirurg?a Tor?cica (SEPAR 1001/2010), Fondo de Investigaci?n Sanitaria (PS09/02457), Barcelona: Fondo de Investigaci?n Sanitaria (FIS PS09/00716), Galdakao: Fondo de Investigaci?n Sanitaria (FIS 09/01511), Huelva: Fondo de Investigaci?n Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud, Oviedo: Fondo de Investigaci?n Sanitaria (FIS PS09/03190), Sweden: All centers were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease, Swedish Research Council for health, working life and welfare, G?teborg: also received further funding from the Swedish Council for Working Life and Social Research. Umea: also received funding from Vasterbotten Country Council ALF grant, Switzerland: The Swiss National Science Foundation (grants nos. 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, and 4026-028099), The Federal Office for Forest, Environment and Landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton's government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Z?rich, the Swiss Lung League, the canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais, and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, and UK: Medical Research Council (grant no.92091), support also provided by the National Institute for Health Research through the Primary Care Research Network., Financial support for ECRHS III: Australia: National Health and Medical Research Council, Estonia: Tartu: the Estonian Ministry of Education ( SF0180060s09 ), France: (All): Ministère de la Santé, Programme Hospitalier de Recherche Clinique national 2010, Bordeaux: INSERM U897 Université Bordeaux segalen, and Paris: Agence Nationale de la Santé, Région Ile de France, domaine d'intérêt majeur, Germany: Erfurt: German Research Foundation ( HE 3294/10-1 ), Hamburg: German Research Foundation ( MA 711/6-1 , NO 262/7-1 ), Iceland: Reykjavik: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation , California, USA , Orkuveita Reykjavikur (Geothermal plant), and Vegagerðin (The Icelandic Road Administration, Italy: All Italian centers were funded by the Italian Ministry of Health , Chiesi Farmaceutici SpA, in addition, Verona was funded by Cariverona Foundation and Education Ministry (Ministero dell'Istruzione, dell'Università e della Ricerca), Norway: Norwegian Research Council (grant no. 214123 ), Western Norway Regional Health Authorities (grant no. 911631 ), and Blond McIndoe Research Foundation, Spain: Fondo de Investigación Sanitaria (PS09/02457, PS09/00716, PS09/01511, PS09/02185, PS09/03190), Servicio Andaluz de Salud, Sociedad Española de Neumología y Cirurgía Torácica ( SEPAR 1001/2010), Fondo de Investigación Sanitaria (PS09/02457), Barcelona: Fondo de Investigación Sanitaria (FIS PS09/00716), Galdakao: Fondo de Investigación Sanitaria (FIS 09/01511), Huelva: Fondo de Investigación Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud, Oviedo: Fondo de Investigación Sanitaria (FIS PS09/03190), Sweden: All centers were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association , The Swedish Association against Lung and Heart Disease , Swedish Research Council for health, working life and welfare, Göteborg: also received further funding from the Swedish Council for Working Life and Social Research . Umea: also received funding from Vasterbotten Country Council ALF grant, Switzerland: The Swiss National Science Foundation (grants nos. 33CSCO-134276/1 , 33CSCO-108796 , 3247BO-104283 , 3247BO-104288 , 3247BO-104284 , 3247-065896 , 3100-059302 , 3200-052720 , 3200-042532 , and 4026-028099 ), The Federal Office for Forest, Environment and Landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton's government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich, the Swiss Lung League , the canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais, and Zurich, SUVA, Freiwillige Akademische Gesellschaft , UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics , European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, and UK: Medical Research Council (grant no. 92091 ), support also provided by the National Institute for Health Research through the Primary Care Research Network ., Conflicts of interest: D. S. Ferreira reports grants from the Asthma Foundation of Victoria , Allen and Hanburys , National Health and Medical Research Council . I. Pin reports travel grants and honoraria from Novartis , Zambon , and AstraZeneca , and nonfinancial support from AGIRàdom. R. Jõgi reports grants from Estonian Research Council Personal Research (grant no. 562 ), and consultancy, lecture, and travel fees from GlaxoSmithKline, Boehringer, and Novartis. The rest of the authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work., Financial support for ECRHS II: Australia: National Health and Medical Research Council, Belgium: Antwerp: Fund for Scientific Research (grant code G.0402.00 ), University of Antwerp , and Flemish Health Ministry, Estonia: Tartu: Estonian Science Foundation (grant no. 4350 ), France: (All) Programme Hospitalier de Recherche Clinique—Direction de la Recherche Clinique de Grenoble 2000 number 2610, Ministry of Health , Ministère de l’Emploi et de la Solidarité, Direction Génerale de la Santé, Centre Hospitalier Universitaire de Grenoble, Bordeaux: Institut Pneumologique d’Aquitaine, Grenoble: Comite des Maladies Respiratoires de l’Isere, Germany: Erfurt: GSF— National Research Centre for Environment and Health , Deutsche Forschungsgemeinschaft (grant code FR1526/1-1 ), Hamburg: GSF— National Research Centre for Environment and Health , Deutsche Forschungsgemeinschaft (grant code MA 711/4-1 ), Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Verona: Ministero dell’Università e della Ricerca Scientifica (MURST), Glaxo Wellcome s.p.a., Norway: Bergen: Norwegian Research Council , Norwegian Asthma and Allergy Association , Glaxo Wellcome AS , and Norway Research Fund, Spain: Fondo de Investigacion Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Hospital Universitario de Albacete, Consejeria de Sanidad, Barcelona: Sociedad Espanola de Neumología y Cirugía Toracica, Public Health Service (grant code R01 HL62633-01 ), Fondo de Investigaciones Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Consell Interdepartamentalde Recerca i Innovació Tecnológica (grant code 1999SGR 00241 ), Instituto de Salud Carlos III, Red de Centros de Epidemiología y Salud Pública, C03/09, Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176, Huelva: Fondo de Investigaciones Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Oviedo: Fondo de Investigaciones Sanitaria ( 97/0035-02 , 97/0035 , 99/0034-01 , 99/0034-02 , 99/0034-04 , 99/0034-06 , 99/350 , and 99/0034-07 ), European Commission ( EU-PEAL PL01237 ), Generalitat de Catalunya ( CIRIT 1999 SGR 00214), Hospital Universitario de Albacete, Sociedad Española de Neumología y Cirugía Torácica ( SEPAR R01 HL62633-01 ), Red de Centros de Epidemiología y Salud Pública (C03/09), Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias (C03/011), and Red de Grupos Infancia y Medio Ambiente (G03/176, Sweden: Göteborg, Umea, AND Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research , Swedish Asthma and Allergy Foundation , Swedish Cancer and Allergy Foundation , and Swedish Council for Working Life and Social Research ( FAS ), Switzerland: Basel: Swiss National Science Foundation , Swiss Federal Office for Education and Science , and Swiss National Accident Insurance Fund, UK: Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign)., Financial support for ECRHS I: The coordination of this work was supported by the European Commission , and the authors and participants are grateful to the late C. Baya and M. Hallen for their help during the study and K. Vuylsteek and the members of the COMAC for their support. The following grants helped to fund the local studies: Australia: Asthma Foundation of Victoria , Allen and Hanbury's, Belgium: Belgian Science Policy Office , National Fund for Scientific Research, Estonia: Estonian Science Foundation (grant no. 1088 ), France: Ministère de la Santé, Glaxo France , Institut Pneumologique d'Aquitaine , Contrat de Plan Etat-Région Languedoc-Rousillon , Caisse nationale de l'assurance maladie des travailleurs salariés, Comité national contre les maladies respiratoires et la tuberculose (90MR/10, 91AF/6), Ministre delegué de la santé, Réseau national de santé publique, France, Germany: Helmholtz Zentrum Munich and Bundesminister für Forschung und Technologie, Italy: Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Consiglio Nazionale delle Ricerche, Regione Veneto (grant RSF no. 381/05.93 ), Portugal: Glaxo Farmacêutica Lda, Sandoz Portugesa, Spain: Fondo de Investigación Sanitaria (nos. 91/0016-060-05/E , 92/0319 , and 93/0393 ), Hospital General de Albacete, Hospital General Juan Ramón Jiménez, Dirección Regional de Salud Pública (Consejería de Sanidad del Principado de Asturias), Consell Interdepartamental de Recerca i Innovació Tecnològica (1997 SGR 00079), and Servicio Andaluz de Salud, Sweden: The Swedish Medical Research Council , the Swedish Heart-Lung Foundation , the Swedish Association against Asthma and Allergy, Switzerland: Swiss National Science Foundation (grant no. 4026-28099 ), and UK: National Asthma Campaign , British Lung Foundation , Department of Health , South Thames Regional Health Authority ., The ALEC study is funded by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement number 633212. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. National funders who supported data collection in the original studies are listed in Appendix E4 in this article's Online Repository at www.jaci-inpractice.org . The funders had no role in the writing of the manuscript or the decision to submit it for publication., Commission of the European Communities, Medical Research Council (MRC), and Ageing Lungs European Cohorts ALEC
- Subjects
Allergy ,Epidemiology ,Respiratory Medicine and Allergy ,Cohort Studies ,Atopy ,Allergic sensitization ,0302 clinical medicine ,Adrenal Cortex Hormones ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Lung ,Sensitization ,Lungmedicin och allergi ,biology ,Inhaled corticosteroids ,Lung function decline ,Pyroglyphidae ,Precision medicine ,3. Good health ,PROPENSITY SCORE ,medicine.anatomical_structure ,IgE ,Cohort study ,Life Sciences & Biomedicine ,Response to corticosteroids ,Asthma ,Adult ,medicine.medical_specialty ,Immunology ,Allergic inflammation ,03 medical and health sciences ,FEV1/FVC ratio ,Internal medicine ,Administration, Inhalation ,Animals ,Humans ,House dust mite ,Science & Technology ,business.industry ,Ageing Lungs in European Cohorts (ALEC) study ,medicine.disease ,biology.organism_classification ,030228 respiratory system ,Cats ,Human medicine ,business - Abstract
BACKGROUND: Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few. OBJECTIVE: To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma. METHODS: We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for 8 years) and FEV1 decline among subjects with asthma over the 2 periods between consecutive examinations. We conducted a cohort study combining data of the 2 periods (906 observations from 745 subjects) to assess whether the association between ICS use and FEV1 decline was modified by allergic sensitization (IgE > 0.35 kU/L for any of house-dust mite, timothy grass, cat, or Cladosporium). RESULTS: FEV1 decline was similar for non-ICS users, as well as ICS users for less than 1.3 years, with and without allergic sensitization. However, among subjects on ICSs for a longer period, sensitization was associated with an attenuated decline (P-interaction = .006): in the group treated for more than 8 years, FEV1 decline was on average 27 mL/y (95% CIBonferroni-adjusted, 11-42) lower for subjects with sensitization compared with nonsensitized subjects. CONCLUSIONS: Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
- Published
- 2020